What does ZRZ Bioenergy do?

ZRZ Bioenergy Ltd is a micro-cap company in the commodity chemicals industry, established in 1911, with a recent net profit of 0 Cr for the quarter ending March 2025 and a market cap of Rs 143 Cr. The company has a negative debt-equity ratio and a return on equity of -0.09%.

Overview: <BR>ZRZ Bioenergy Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History: <BR>ZRZ Bioenergy Ltd was initially established in 1911 as a proprietary concern and underwent several status changes, becoming a Private Limited Company in 1939, then a Public Limited Company in 1961, and changing its name to Gujchem Distillers India Limited in 1974. The latest quarterly results reported net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 143 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.14 <BR>Return on Equity: -0.09% <BR>Price to Book: 1.03<BR><BR>Contact Details: <BR>Address: No 6 2nd Flr National Chambers, Nr City Gold Ashram Road Ahmedabad Gujarat : 380009 <BR>Tel: 91-7926580893 <BR>Email: gujcheminvestors@gmail.com <BR>Website: http://www.gujchemdistillers.com

Who are in the management team of ZRZ Bioenergy?

As of March 2023, the management team of ZRZ Bioenergy includes Sagar Shah (Chairman), Sangeeta Khyani (Company Secretary), Barkha Balkrushnan Deshmukh and Sunil Kondiba Kalhapure (Independent Directors), Viraj Samirbhai Shah (Whole-time Director), and Rajasvee Shah (Non-Executive Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of ZRZ Bioenergy includes the following members:<BR><BR>1. Sagar Shah - Chairman (Non-Executive)<BR>2. Sangeeta Khyani - Company Secretary & Compliance Officer<BR>3. Barkha Balkrushnan Deshmukh - Independent Director<BR>4. Viraj Samirbhai Shah - Whole-time Director<BR>5. Sunil Kondiba Kalhapure - Independent Director<BR>6. Rajasvee Shah - Non-Executive Director<BR><BR>Each member plays a distinct role within the organization, contributing to its governance and operational management.

Has ZRZ Bioenergy declared dividend?

No Dividend History Available

Who are the peers of the ZRZ Bioenergy?

ZRZ Bioenergy's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Archit Organosys, Polychem, Shreyas Interm., and Sh. Hari Chem. ZRZ Bioenergy has an average management risk and a 1-year return of 110.08%, outperforming Polychem but below India Glycols' 150.38%.

Peers: The peers of ZRZ Bioenergy are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Archit Organosys, Polychem, Shreyas Interm., and Sh. Hari Chem.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar, and Average management risk is present at Tata Chemicals, India Glycols, and the rest. Below Average management risk is noted for Fischer Medical, ZRZ Bioenergy, Archit Organosys, Sh. Hari Chem, and the rest. Growth ratings show Good growth at Archit Organosys and Sh. Hari Chem, while Average growth is seen at Fischer Medical and ZRZ Bioenergy, and Below Average growth is noted for Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Polychem, and the rest. Capital Structure ratings are Excellent at GHCL, Good at Fischer Medical and Polychem, Average at Tata Chemicals, Archit Organosys, and ZRZ Bioenergy, and Below Average at Chemplast Sanmar, India Glycols, Sh. Hari Chem, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is India Glycols at 150.38%, while the lowest is Polychem at -30.89%. ZRZ Bioenergy's 1-year return of 110.08% is significantly higher than Polychem's. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Polychem, and Shreyas Interm.

Is ZRZ Bioenergy overvalued or undervalued?

As of February 14, 2025, ZRZ Bioenergy is considered risky and overvalued with a PE ratio of -146.27 and significant financial distress, contrasting sharply with peers like Godrej Industries and Deepak Nitrite, despite having outperformed the Sensex over the past year.

As of 14 February 2025, the valuation grade for ZRZ Bioenergy has moved from very expensive to risky. The company is currently assessed as overvalued. Key ratios reveal a PE ratio of -146.27, an EV to EBITDA of -127.26, and a Price to Book Value of 1.05, indicating significant financial distress and a lack of profitability.<BR><BR>In comparison to its peers, ZRZ Bioenergy's valuation metrics starkly contrast with companies like Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, and Deepak Nitrite, with a PE of 37.97 and an EV to EBITDA of 24.57. The substantial differences in these ratios highlight the challenges ZRZ Bioenergy faces within the commodity chemicals sector. Additionally, while ZRZ Bioenergy has outperformed the Sensex over the past year with a return of 87.11% compared to the Sensex's 7.65%, the underlying valuation suggests that this performance may not be sustainable given its current financial metrics.

What is the technical trend for ZRZ Bioenergy?

As of May 28, 2025, ZRZ Bioenergy shows a mildly bullish trend supported by the weekly MACD and Bollinger Bands, despite mixed signals from daily moving averages and the monthly MACD.

As of 28 May 2025, the technical trend for ZRZ Bioenergy has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. However, daily moving averages are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly and mildly bearish on the monthly, adding to the mixed signals. Dow Theory indicates a mildly bullish stance on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands.

Who are the top shareholders of the ZRZ Bioenergy?

The top shareholders of ZRZ Bioenergy are Zr2 Group Holdings Ltd with 60.96% of shares, followed by public shareholder Manish Ruparel at 9.92%. Individual investors collectively own 37.43%, with no mutual funds or foreign institutional investors involved.

The top shareholders of ZRZ Bioenergy include Zr2 Group Holdings Ltd, which holds a significant 60.96% of the shares. Additionally, the highest public shareholder is Manish Ruparel, who owns 9.92%. Individual investors collectively hold 37.43% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) involved in the company's shareholding.

How big is ZRZ Bioenergy?

As of 24th July, ZRZ Bioenergy Ltd has a market capitalization of 135.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.19 Cr in the latest four quarters. Shareholder's Funds are 16.85 Cr and Total Assets amount to 39.11 Cr as of March 2024.

As of 24th July, ZRZ Bioenergy Ltd has a market capitalization of 135.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, ZRZ Bioenergy reported Net Sales of 0.00 Cr and a Net Profit loss of 0.19 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 16.85 Cr and Total Assets of 39.11 Cr.

Are ZR2 Bioenergy latest results good or bad?

ZR2 Bioenergy's latest results show improved profitability with a Profit After Tax increase, but net sales remain flat and operational challenges persist, leading to a 'Sell' rating from analysts. Overall, the results are mixed, indicating both positive and negative aspects.

ZR2 Bioenergy's latest results present a mixed picture. On one hand, the company has shown a significant improvement in profitability, with Profit After Tax (PAT) rising to Rs 0.42 crore for the latest six-month period, a substantial increase from Rs 0.06 crore in the previous year. This indicates that the company is on a positive trajectory in terms of profitability.<BR><BR>However, the overall financial performance remains flat, with net sales showing no growth compared to the previous year. Additionally, the Debtors Turnover Ratio has declined to 0.00 times, suggesting challenges in the company's ability to manage its debts effectively. This raises concerns about operational efficiency.<BR><BR>Furthermore, the stock is currently rated as a 'Sell' by MarketsMOJO, which reflects a cautious outlook from market analysts. Overall, while there are positive signs in profitability, the lack of growth in sales and operational challenges indicate that the results are not entirely favorable.

When is the next results date for ZR2 Bioenergy?

ZR2 Bioenergy will announce its results on 14 November 2025.

ZR2 Bioenergy will declare its results on 14 November 2025.

Should I buy, sell or hold ZR2 Bioenergy?

How has been the historical performance of ZR2 Bioenergy?

ZR2 Bioenergy's historical performance from March 2022 to March 2025 shows increased net sales and operating income, but a decline in profitability and operational efficiency, with profit after tax dropping significantly and operating profit margin turning negative. Despite stable liabilities and positive cash flow from operations, the company faced challenges in maintaining profitability.

Answer:<BR>The historical performance of ZR2 Bioenergy shows a mixed trend in financial metrics from March 2022 to March 2025.<BR><BR>Breakdown:<BR>ZR2 Bioenergy's net sales increased from 1.16 Cr in March 2022 to 1.49 Cr in March 2025, while total operating income also rose to 1.49 Cr from 1.16 Cr during the same period. However, the company's total expenditure saw a significant rise from 1.11 Cr to 1.90 Cr, leading to an operating profit (PBDIT) decline from 0.32 Cr to 0.23 Cr. The operating profit margin (excluding other income) fell sharply from 4.31% to -27.52%, indicating a deterioration in operational efficiency. Profit before tax decreased from 0.32 Cr to 0.20 Cr, and profit after tax dropped significantly from 0.39 Cr to 0.09 Cr, resulting in a PAT margin decline from 33.62% to 6.04%. On the balance sheet, total liabilities remained stable at 139.50 Cr, with shareholder's funds at 139.34 Cr. The cash flow from operating activities was positive at 31.00 Cr, while cash flow from investing activities was negative at -116.00 Cr, and financing activities contributed 100.00 Cr, leading to a net cash inflow of 14.00 Cr and a closing cash balance of 19.00 Cr. Overall, while sales and income showed growth, profitability and operational efficiency faced challenges.

Which are the latest news on ZR2 Bioenergy?

Why is ZR2 Bioenergy falling/rising?

As of 04-Dec, ZR2 Bioenergy Ltd's stock price is rising to 317.00, reflecting a short-term recovery with a recent gain of 11.74% over the past week, despite a year-to-date decline of 23.72%. However, decreased investor participation may impact future price movements.

As of 04-Dec, ZR2 Bioenergy Ltd's stock price is rising, currently at 317.00, with a change of 0.8 (0.25%) upwards. The stock has shown a strong performance over the past week, gaining 11.74%, while the benchmark Sensex has declined by 0.53%. Additionally, the stock has experienced consecutive gains over the last two days, with a total increase of 6.73% during this period. <BR><BR>Despite a negative performance over the longer term, including a year-to-date decline of 23.72%, the recent upward trend indicates a short-term recovery. The stock is currently outperforming its sector by 0.46%. However, it is important to note that investor participation has decreased, with delivery volume falling by 82.14% compared to the 5-day average, which may affect future price movements. Overall, the recent gains can be attributed to a short-term positive momentum, despite the longer-term challenges reflected in the year-to-date performance.